Abstract
Background Adoptive immunotherapy using tumor-infiltrating lymphocytes (TILs) has been used to treat malignant melanoma and renal cell carcinoma, although the clinical efficacy of this method has not yet been proved. To improve clinical efficacy, it is important to induce sufficient amounts of tumor-infiltrating lymphocytes to fight the tumor. In this study, we investigated the clinical efficacy of adoptive immunotherapy using interleukin (IL)-2 activated tumor-infiltrating lymphocytes combined with IL-4.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.